Bioprocess Digital Twin Market Report 2026

The bioprocess digital twin market size has grown exponentially in recent years. It will grow from $1.63 billion in 2025 to $2.02 billion in 2026 at a compound annual growth rate (CAGR) of 24.4%. The growth in the historic period can be attributed to increasing complexity of biologics manufacturing processes, growing availability of process sensor data, rising adoption of advanced bioprocess control systems, increasing focus on yield optimization, expansion of digital manufacturing initiatives.

The bioprocess digital twin market size is expected to see exponential growth in the next few years. It will grow to $4.88 billion in 2030 at a compound annual growth rate (CAGR) of 24.6%. The growth in the forecast period can be attributed to increasing investments in smart biomanufacturing platforms, rising demand for real-time decision support tools, expansion of digital quality management systems, growing regulatory acceptance of digital twins, increasing focus on cost and risk reduction. Major trends in the forecast period include increasing adoption of real-time bioprocess simulation, rising integration of predictive analytics in manufacturing, expansion of closed-loop process optimization, growing use of virtual commissioning tools, enhanced focus on regulatory-compliant digital validation.

The rise in biopharmaceutical production is anticipated to drive the growth of the bioprocess digital twin market in the coming years. Biopharmaceutical production refers to the manufacturing and development of therapeutic products derived from biological sources, such as living cells, proteins, and nucleic acids. Growth in biopharmaceutical production is driven by increasing investment in research and development, as pharmaceutical companies allocate substantial resources to discover and manufacture innovative biological therapies for chronic and rare diseases. Higher biopharmaceutical production volumes create greater demand for digital twin technologies that enable real-time monitoring, optimization, and predictive modeling of complex bioprocessing systems. For example, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, total pharmaceutical production in Europe accounted for €390.0 billion ($422,803 million) in 2023, up from €363.3 billion ($393,857 million) in 2022. Therefore, the rise in biopharmaceutical production is driving the growth of the bioprocess digital twin market.

Companies operating in the bioprocess digital twin market are focusing on technological advancement in process simulation, such as digital twin-based bioprocess development platforms, to enhance process predictability, improve product quality, and reduce development timelines. A digital twin-based bioprocess development platform creates a virtual model of an actual bioprocess using real-time data, advanced modeling, and simulation to accurately predict process performance and enhance product quality by allowing process scenarios to be evaluated digitally before physical execution. For example, in January 2026, WuXi Biologics, a China-based contract research, development, and manufacturing organization, launched PatroLabTM, a state-of-the-art bioprocess digital twin platform to support advanced bioprocess development and manufacturing. It integrates real-time process monitoring with Raman-based Process Analytical Technology (PAT) and predictive in-silico modeling. The platform continuously incorporates live process data into virtual models, enabling real-time analytics and proactive process control. PatroLab helps detect process deviations early, reduce operational risks, and improve process consistency.

In July 2025, Repligen Corporation, a US-based provider of bioprocessing technologies and solutions, entered into a strategic partnership with Novasign to advance bioprocess digitalization by leveraging digital twin and predictive modeling technologies for smarter biomanufacturing. The partnership aims to integrate Novasign’s bioprocess digital twin platform into Repligen’s bioprocessing portfolio, enabling enhanced process understanding, virtual simulation, and optimization across biologics development and manufacturing. Novasign is an Austria-based developer of bioprocess digital twins for biologics development and manufacturing.

Major companies operating in the bioprocess digital twin market are Siemens Aktiengesellschaft, General Electric Company, Schneider Electric SE, Honeywell International Inc., ABB Ltd, Emerson Electric Co., Rockwell Automation Inc., Dassault Systèmes SE, Cytiva Sweden AB, Mettler Toledo International Inc., Sartorius Aktiengesellschaft, WuXi Biologics Cayman Inc., ANSYS Inc., PTC Inc., AVEVA Group plc, Aspen Technology Inc., Aizon Ltd, TwinThread Inc., Intelligen Inc., and Novasign GmbH.

Tariffs are influencing the bioprocess digital twin market by increasing costs of imported sensors, industrial computing hardware, data acquisition systems, and specialized software infrastructure used for real-time modeling and simulation. Pharmaceutical and biotechnology manufacturers in North America and Europe are most affected due to reliance on imported digital hardware components, while Asia-Pacific faces cost pressures on deployment of large-scale digital platforms. These tariffs are raising implementation costs and extending adoption timelines. At the same time, they are encouraging domestic software development, localized system integration services, and regional innovation in bioprocess digital technologies.

The bioprocess digital twin market research report is one of a series of new reports that provides bioprocess digital twin market statistics, including bioprocess digital twin industry global market size, regional shares, competitors with a bioprocess digital twin market share, detailed bioprocess digital twin market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocess digital twin industry. This bioprocess digital twin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A bioprocess digital twin is a virtual model that replicates a biological manufacturing process and simulates its performance in real time. It combines sensor data, laboratory outputs, and historical process information to forecast results and optimize operations. This technology improves efficiency, lowers costs, and enhances product quality by allowing virtual testing and refinement before implementing changes in physical production systems.

The primary components of bioprocess digital twin include software, hardware, and services. Software refers to platforms that simulate, monitor, and optimize bioprocess operations in real time to enhance efficiency, quality, and predictive insights. These solutions are deployed in modes such as on-premises and cloud. They are applied across areas including process optimization, predictive maintenance, quality management, performance monitoring, and other applications, and are utilized by end users including pharmaceutical and biotechnology companies, contract manufacturing organizations, academic and research institutes, and other end users.

The bioprocess digital twin market consists of revenues earned by entities by providing services such as process modeling and simulation services, bioprocess optimization services, predictive analytics and forecasting services, real-time monitoring and visualization services, system integration and deployment services, validation and regulatory support services, and training and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess digital twin market also includes sales of digital twin software platforms, bioprocess simulation tools, data analytics and visualization tools, process control and optimization software, virtual commissioning tools, and lifecycle management software. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.